Chip-based gene technology increasingly tying diagnostic, pharmaceutical development -- SB's Leschly.
This article was originally published in The Gray Sheet
Executive Summary
CHIP-BASED GENETIC TECHNOLOGY's LINKAGE OF DIAGNOSTIC AND DRUG DEVELOPMENT activities will become apparent over the next several years as commercial applications of genomics -- the study of gene location, structure and function -- are brought to bear through increased collaboration among the medical device, biotechnology and pharmaceutical industries, according to SmithKline Beecham Chief Executive Jan Leschly.
You may also be interested in...
QUOTED. 27 November 2020. Agam Sharda.
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
Real World Data Failed To Impress Kaftrio’s European Reviewers
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic Clears Up Confusion Over Validity Of GMP Certificates
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: